Ueda Shinichiro

写真a

Title

Professor

Researcher Number(JSPS Kakenhi)

80285105
To the head of this page.▲

Current Affiliation Organization 【 display / non-display 】

  • Duty   University of the Ryukyus   Graduate School of Medicine   Professor  

To the head of this page.▲

Academic degree 【 display / non-display 】

  • Yokohama City University -  Doctor of Medicine

To the head of this page.▲

External Career 【 display / non-display 】

  • 2001.12
    　
    　

    University of the Ryukyus, Graduate School of Medicine, Professor  

To the head of this page.▲

Research Interests 【 display / non-display 】

  • ヒト血管内皮機能

  • 平滑筋機能,心血管薬薬効評価のための代替エンドポイントの開発,降圧利尿薬ランダム化臨床試験,代謝症候群における血管機能

  • インスリン感受性への治療介入と評価

To the head of this page.▲

Published Papers 【 display / non-display 】

  • Association of schizophrenia with fracture-related femoral neck displacement: A cross-sectional retrospective study.

    Yukiyo Inoue, Akihiro Tokushige, Takeshi Kinjyo, Shinichiro Ueda

    PCN reports : psychiatry and clinical neurosciences   3 ( 2 ) e195   2024.06 [ Peer Review Accepted ]

    Type of publication: Research paper (scientific journal)

    　View Summary

    AIM: Fracture-related femoral neck displacement is more likely in patients with schizophrenia because of delayed diagnosis, as these patients frequently have less severe fracture-associated subjective symptoms. This study aimed to investigate the association of schizophrenia with the risk of fracture-related femoral neck displacement in hospitalized patients. METHODS: We retrospectively analyzed the medical records of patients with femoral neck fractures treated between April 2013 and March 2018 at a single institution. Multivariate logistic regression was used to explore the relationship between schizophrenia and fracture-related femoral neck displacement after adjusting for risk factors. RESULTS: We compared 30 and 194 patients with and without schizophrenia, respectively. The prevalence of fracture-related displacement was 80.0% in patients with schizophrenia and 62.4% in the controls (p = 0.06). After adjusting for confounding variables, schizophrenia significantly correlated with fracture-related femoral neck displacement (odds ratio: 4.74, 95% confidence interval: 1.09-20.60, p = 0.0378). CONCLUSIONS: Schizophrenia is associated with a higher risk of severe femoral neck fracture. To improve outcomes and alleviate the societal burden of femoral neck fractures, early radiographic assessment and surgical intervention for femoral fractures are essential for patients with schizophrenia, even in those without pain symptoms.

  • Analysis of in-hospital deaths in patients with critical limb ischemia necessitating invasive treatments: based on a Japanese nationwide database

    Iwata, K; Nitta, M; Kaneko, M; Fushimi, K; Ueda, S; Shimizu, S

    CARDIOVASCULAR INTERVENTION AND THERAPEUTICS ( Cardiovascular Intervention and Therapeutics )    2024.04 [ Peer Review Accepted ]

    Type of publication: Research paper (scientific journal)

    • Access this article
      DOI
    • Search related information
      PubMed

  • Agile 3+and Agile 4, noninvasive tests for liver fibrosis, are excellent formulae to predict liver-related events in nonalcoholic fatty liver disease

    Miura, K; Hayashi, H; Kamada, Y; Fujii, H; Takahashi, H; Oeda, S; Iwaki, M; Kawaguchi, T; Tomita, E; Yoneda, M; Tokushige, A; Ueda, S; Aishima, S; Sumida, Y; Nakajima, A; Okanoue, T

    HEPATOLOGY RESEARCH ( Hepatology Research )  53 ( 10 ) 978 - 988   2023.10 [ Peer Review Accepted ]

    Type of publication: Research paper (scientific journal)

    　View Summary

    AIM: The noninvasive tests (NITs) Agile 3+ and Agile 4 effectively identify patients with nonalcoholic fatty liver disease (NAFLD) complicated with advanced fibrosis (F3-4) and cirrhosis (F4), respectively. Little information is available on associations between Agile scores and intra-/extrahepatic events. The aim of this study was to determine the predictive performance of Agile scores for intra-/extrahepatic events in Asian patients with biopsy-proven NAFLD. METHODS: We undertook a retrospective multicenter cohort study to investigate associations between intra-/extrahepatic events and two Agile scores, Agile 3+ and Agile 4. The scores were obtained by combining clinical parameters and liver stiffness measurement using transient elastography. RESULTS: Among 403 enrolled patients, 11 had liver-related events (LREs), including seven with hepatocellular carcinoma (HCC). The incidence of LREs and HCC showed a stepwise increase in the advanced fibrosis group (F3-4), Agile 3+ rule-in (F3-4, highly suspected), and Agile 4 rule-in (F4, highly suspected) groups, compared to their counterparts. Hazard ratios for LREs in the advanced fibrosis group, Agile 3+ rule-in, and Agile 4 rule-in groups were 4.05 (p = 0.03), 23.5 (p = 0.003), and 45.5 (p < 0.001), respectively. The predictive performance results for Agile 3+ and Agile 4 were 0.780 and 0.866, respectively, which were higher than for fibrosis (0.595). Unlike for LREs, Agile scores failed to identify patients with extrahepatic events, including cardiovascular events and extrahepatic cancer. CONCLUSIONS: Agile 3+ and Agile 4 scores are excellent NITs for predicting LREs in patients with NAFLD, possibly without histological assessment.

    • Access this article
      DOI
    • Search related information
      PubMed

  • Comparison of the Quality of Phase Ⅲ Non-commercial Clinical Trials in Japan, the United States, and the United Kingdom before the Implementation of the New Japanese Clinical Trials Act

    Yamauchi S.

    臨床薬理 ( 一般社団法人 日本臨床薬理学会 )  54 ( 3 ) 95 - 101   2023.05 [ Peer Review Accepted ]

    Type of publication: Research paper (scientific journal)

    　View Summary

    <p>Recent research misconduct, represented by the valsartan scandal, has raised questions about the quality of non-commercial trials not for regulatory approval in Japan. Unlike in the US and Europe, non-commercial clinical trials are not regulated by law in Japan, which was believed to be a reason why quality could not be guaranteed. However, until now, few studies have compared the quality of clinical studies among countries. In this study, the quality of Japanese non-commercial phase Ⅲ trials before the implementation of the Clinical Trials Act (CTA) in 2018 was compared with Western non-commercial trials registered in the database using study design as quality indicators. The study found a lower proportion of randomized, controlled trials (RCTs) (70％ in Japan, 89％ in the US, and 88％ in the UK) and fewer blinded designs (46％ in Japan, 59％ in the US, and 52％ in the UK) in non-commercial trials in Japan. Single-arm trials not for either cancer or rare diseases, which are usually considered low quality because of a lack of fair comparison, were more common in Japan (82％) than in the US (76％) and the UK (50％). In terms of endpoint setting, most non-commercial trials in Japan had surrogate endpoints, with only a few trials using true endpoints (5％) compared to the US (24％) and the UK (40％). A comparison of these quality indicators in Japanese non-commercial trials before and after the CTA implementation showed no increases in the proportion of RCT and blinded designs, but an increase in the proportion of trials using true endpoints and appropriate use of single-arm design. In conclusion, the lack of legal regulation in Japan may have indirectly affected the quality of non-commercial phase Ⅲ trials in Japan at the time. Implementation of the CTA has contributed to some quality improvements, but the effect is limited at present. </p>

  • Association of Serum Albumin Levels and Long-Term Prognosis in Patients with Biopsy-Confirmed Nonalcoholic Fatty Liver Disease

    Takahashi, H; Kawanaka, M; Fujii, H; Iwaki, M; Hayashi, H; Toyoda, H; Oeda, S; Hyogo, H; Morishita, A; Munekage, K; Kawata, K; Tsutsumi, T; Sawada, K; Maeshiro, T; Tobita, H; Yoshida, Y; Naito, M; Araki, A; Arakaki, S; Kawaguchi, T; Noritake, H; Ono, M; Masaki, T; Yasuda, S; Tomita, E; Yoneda, M; Tokushige, A; Kamada, Y; Ueda, S; Aishima, S; Sumida, Y; Nakajima, A; Okanoue, T

    NUTRIENTS ( Nutrients )  15 ( 9 )   2023.04 [ Peer Review Accepted ]

    Type of publication: Research paper (scientific journal)

    　View Summary

    The relationship between baseline serum albumin level and long-term prognosis of patients with nonalcoholic fatty liver disease (NAFLD) remains unknown. This is a sub-analysis of the CLIONE (Clinical Outcome Nonalcoholic Fatty Liver Disease) study. The main outcomes were: death or orthotopic liver transplantation (OLT), liver-related death, and liver-related events (hepatocellular carcinoma [HCC], decompensated cirrhosis, and gastroesophageal varices/bleeding). 1383 Japanese patients with biopsy-confirmed NAFLD were analyzed. They were divided into 3 groups based on serum albumin: high (>4.0 g/dL), intermediate (3.5–4.0 g/dL), and low (<3.5 g/dL). Unadjusted hazard ratio [HR] of the intermediate albumin group, compared with the high albumin group, were 3.6 for death or OLT, 11.2 for liver-related death, 4.6 for HCC, 8.2 for decompensated cirrhosis, and 6.2 for gastroesophageal varices (all risks were statistically significant). After adjusting confounding factors, albumin remained significantly associated with death or OLT (intermediate vs. high albumin group: HR 3.06, 95% confidence interval [CI] 1.59–5.91, p < 0.001; low vs. high albumin group: HR 22.9, 95% CI 8.21–63.9, p < 0.001). Among biopsy-confirmed NAFLD patients, those with intermediate or low serum albumin had a significantly higher risk of death or OLT than those with high serum albumin.

display all >>

To the head of this page.▲

Other Papers 【 display / non-display 】

  • 5. Pit Fall of Clinical Trials for Pharmaceuticals From the Standpoint of Clinical Pharmacology. Trials, Whom is it for ?

    UEDA Shinichiro

    Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics ( The Japanese Society of Clinical Pharmacology and Therapeutics )  50 ( 3 ) 125 - 129   2019

     

    DOI

  • 慢性疾患レジストリで橋をかける産官学そして患者 RCT on Registry,品質管理,標準化 慢性疾患レジストリと臨床試験実施における活用,RCT on registry

    植田 真一郎, 徳重 明央, 比嘉 真由美, 藤田 優子, 宇根 かおり, 池原 由美

    臨床薬理 ( (一社)日本臨床薬理学会 )  48 ( Suppl. ) S208 - S208   2017.11

     

  • 降圧薬投与下での内皮機能と発症前血管損傷の進行 FMD-J多施設共同前向き研究の結果(Endothelial Function and the Progression of Preclinical Vascular Damages Under Antihypertensive Medication: The Results of FMD-J Multi-Center Prospective Study)

    冨山 博史, 山科 章, 前村 浩二, 木庭 新治, 山崎 力, 佐田 政隆, 石津 智子, 伊藤 浩, 竹本 恭彦, 東 幸仁, 鈴木 亨, 大屋 祐輔, 植田 真一郎, 苅尾 七臣, 古川 泰司, 高瀬 凡平, 井上 晃男, 野出 孝一, 松本 知沙, 石橋 豊

    日本循環器学会学術集会抄録集 ( (一社)日本循環器学会 )  81回   LBCSP1 - 6   2017.03  [Refereed]

     

  • 臨床研究教育プログラム参加医師の背景分析に基づくキャリアパスの提案

    池原 由美, 大城 絢子, 齋藤 麻衣子, 植田 真一郎

    臨床薬理 ( (一社)日本臨床薬理学会 )  47 ( Suppl. ) S286 - S286   2016.10  [Refereed]

     

  • 臨床現場を反映した臨床研究教育プログラムにおけるADDIEモデルの適用結果と適合性の検証

    大城 絢子, 池原 由美, 植田 真一郎

    医学教育 ( (一社)日本医学教育学会 )  47 ( Suppl. ) 207 - 207   2016.07  [Refereed]

     

display all >>

To the head of this page.▲

Presentations 【 display / non-display 】

To the head of this page.▲

Grant-in-Aid for Scientific Research 【 display / non-display 】

To the head of this page.▲

Other External funds 【 display / non-display 】

  • Project Year: 2020.04  -  2021.03 

    Offer Organization: AMED

To the head of this page.▲